TransMedics' Technology Poised To Transform Underpenetrated $8B Organ Transplant Market, Analyst Expects 22% Upside
TransMedics' Technology Poised To Transform Underpenetrated $8B Organ Transplant Market, Analyst Expects 22% Upside
Needham analyst initiated coverage on TransMedics Group Inc (NASDAQ:TMDX), a commercial-stage medical technology company focused on organ transplant therapy for end-stage organ failure patients across multiple disease states.
Needham分析师对TransMedics Group Inc (NASDAQ:TMDX)进行了初步涵盖，该公司是一家专注于为末期器官衰竭患者提供器官移植治疗的商业阶段医疗科技公司。
The company has developed the Organ Care System (OCS), which is designed to better preserve, assess, and maintain donor organs.
该公司开发了Organ Care System (OCS)，旨在更好地保存、评估和维护供体器官。
Needham notes that TransMedics' OCS technology, backed by extensive clinical data and multiple FDA approvals, is transforming the underpenetrated organ transplant market, which is over $8 billion and has less than 6% penetration.
Needham指出，TransMedics的OCS技术凭借广泛的临床数据和多个FDA批准，正在改变渗透率低于6%的器官移植市场，该市场规模超过80亿美元。
Also Read: This MedTech Company Has Market Expansion Opportunity, Says Bullish Analyst.
还阅读：这家医疗科技公司有着市场扩张机会，看好分析师表示。
The company's National OCS Program (NOP), a turnkey organ procurement service, has been a significant growth driver.
该公司的National OCS Program (NOP)是一个一站式器官供应服务，已成为重要的增长驱动因素。
TransMedics has its planes, a staff of surgeons and clinical specialists, and a logistics team that enables transplant centers to procure and transplant more organs.
TransMedics拥有自己的飞机、队伍由外科医生和临床专家组成，以及一个物流团队，使移植中心能够采购和移植更多器官。
Needham notes that NOP is driving the increasing use of OCS, and TransMedics' revenue growth accelerated from 18% in 2021 before NOP to 209% in 2022 after NOP.
Needham指出，NOP推动了OCS的日益增多的使用，TransMedics的营业收入增长从NOP之前的2021年的18%加速到NOP之后的2022年的209%。
TransMedics is projected to become profitable in 2024, and operating margin, EPS, and cash flow are expected to improve rapidly in 2025-2026.
预计TransMedics将在2024年实现盈利，并且营业利润率、每股收益和现金流量预计在2025-2026年有快速改善。
The analyst initiated with a Buy rating and a price target of $208, representing an upside of almost 22%, citing that the company is 'bending the organ transplant curve.'
分析师开始给予买入评级和208美元的目标价，表示涨幅接近22%，称该公司正在“改变器官移植曲线”。
Needham writes, "We believe that TransMedics' valuation is reasonable considering its growth rate and potential for upside to consensus."
Needham写道：“考虑到TransMedics的增长率和与共识的上涨潜力，我们认为其估值是合理的。”
In the second quarter of 2024, revenue reached $114.3 million, a 118% year-over-year increase driven primarily by the increase in utilization of the Organ Care System across all three organs through the National OCS Program and additional revenue generated by the launch of TransMedics logistics services.
在2024年第二季度，营业收入达到1.143亿元，同比增长118%，主要受到全国OCS计划对三个器官的利用率提高以及TransMedics物流服务推出带来的额外收入的推动。
Price Action: TMDX stock is up 2.58% at $170.47 at the last check on Wednesday.
股票价格：截至上周三，TMDX股票上涨2.58%，报170.47美元。
- Wegovy Now Available Through Sesame's $249 Monthly Compounded Program Despite Supply Shortages.
- 尽管供应不足，Wegovy现在可以通过Sesame的249美元每月复利计划购买。